Answers are grounded in this paper and cite their sources.
The radioprotective agent, WR-2721 (S-2-[3-aminopropylamino] ethylphosphorothioate), has been tested (or its ability to protect mice against X-ray-induced lethality and against X-ray-induced skin ulceration, and for its ability to protect a transplantable mammary tumor against radiation-induced inhibition of transplantability. Injection of WR-2721 (500 mg/kg) 15 minutes before X-ray exposures increases the dose required to induce 50% lethality within 30 days (LD50/30) by 160–170%, increases the X-ray dose required to induce skin ulceration in 50% of the mice by 140%, but increases the dose required to inhibit tumor transplantability by only 15%. This differential protective activity, even though limited in scope, should be investigated further to assess the potential usefulness of radioprotective agents in radiotherapy.
No takes yet. Share an insight, caveat, or question.
Yuhas et al. (1969) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: